Company news

Viva Biotech Holdings news in 2025

Viva Biotech Holdings's news releases, calls and decks from 2025, newest first.

View company

Adventures in DMPK: Viva Biotech's One-Stop Pharmacology Platform Cross New Modalities

December 29, 2025

Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.

December 15, 2025

Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry

September 29, 2025

Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights

September 2, 2025

Viva Biotech Announces Its 2025 Interim Results: CRO Revenue Returned to Positive Growth, New CDMO Commercialization Projects Showed Promising Growth

August 28, 2025

Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection

March 28, 2025

Viva Biotech Announces 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D

March 27, 2025

Decks in 2025